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Abstract: The role of fibre intake in the management of patients with pancreatic disease is still
controversial. In acute pancreatitis, a prebiotic enriched diet is associated with low rates of pancreatic
necrosis infection, hospital stay, systemic inflammatory response syndrome and multiorgan failure.
This protective effect seems to be connected with the ability of fibre to stabilise the disturbed intestinal
barrier homeostasis and to reduce the infection rate. On the other hand, in patients with exocrine
pancreatic insufficiency, a high content fibre diet is associated with an increased wet fecal weight and
fecal fat excretion because of the fibre inhibition of pancreatic enzymes. The mechanism by which
dietary fibre reduces the pancreatic enzyme activity is still not clear. It seems likely that pancreatic
enzymes are absorbed on the fibre surface or entrapped in pectin, a gel-like substance, and are likely
inactivated by anti-nutrient compounds present in some foods. The aim of the present review is to
highlight the current knowledge on the role of fibre in the nutritional management of patients with
pancreatic disorders.
Keywords: pancreatitis; pancreatic exocrine insufficiency; nutritional management; maldigestion;
diet; fibre
1. Introduction
1.1. Fibres in Human Health
According to major food and health organisations such as the European Food Safety
Authority (EFSA), the Food and Agricultural Organisation (FAO)/World Health Organisation (WHO),
the Scientific Advisory Committee on Nutrition (SACN), the Nordic Nutrient Recommendations
(NNR), and the German Nutrition Society (DGE), people’s health benefits greatly from dietary fibre,
e.g., on gastrointestinal disorders and risk in non-communicable diseases [1]. In regards to the most
common diseases worldwide, several studies focused their attention on the protective effect of dietary
fibre on cardiovascular disease (CVD) likely related to the reduction of metabolic syndrome (MetS),
one of its promoting factors [2–4]. An inverse relationship has been found between high consumption
of dietary fibre and MetS with a lower risk of MetS for every 10 g/day fibre increment, especially with
cereal and fruit rather than vegetables [5]. Their positive effects on MetS are probably due to promotion
of satiety, delayed gastric emptying, reduction of macronutrients absorption with subsequent weight
loss in obese patients, improvement of insulin sensitivity, hypertension, reduction of cholesterol plasma
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levels, triglycerides levels and triglycerides to HDL-cholesterol ratio [4,6]. Similar studies in the
pancreatic setting are conflicting. Recently, dietary fibre intake has been reported to be protective
against the occurrence of acute pancreatitis (AP) by Setiawan et al. [7]. This is in contrast to a previous
prospective cohort study [8] in which no association was found. Studies on the effects of dietary
fibre intake on pancreatitis management are scarce and are hindered by the lack of specific pancreatic
“disease indicators” as well as by the dichotomy of fibre effects, as discussed later, between pancreatic
conditions with or without pancreatic exocrine insufficiency (PEI).
The main beneficial effects on human health are due to physicochemical fibre properties, namely
their solubility in water, fermentability and viscosity. As far as solubility is concerned, soluble fibre
dissolves in water and gastrointestinal fluids, is transformed into a gel-like substance, which is digested
by bacteria in the large bowel, and gases and few calories are released. On the contrary, insoluble fibre
does not dissolve in water or gastrointestinal fluids, it remains unchanged as it moves through the
digestive tract, and therefore, does not result in a source of calories [9]. A healthy diet contains a mix
of both soluble and insoluble fibre. Soluble fibre is more present in fruits (apple, citrus), vegetables,
legumes, potatoes, seaweed extracts, microbial gums; while insoluble fibre is more common in plants
(vegetables cell walls, sugar beet, various brans), green bananas and cereal grains [9,10].
Fermentability by bacteria in the large bowel contributes to microbial diversity, whereas viscosity,
that is the capability of fibre to form a gel-like substance when dissolved in intestinal fluids, influences
nutrients absorption, a property exploited to control glucose and lipid metabolism [9]. Besides the
physicochemical properties of fibre, it also provides humans with vitamins, minerals and anti-oxidant
compounds that can contribute to their health [11,12]. In adults, the recommended amount of dietary
fibre ranges from 25 to 38 g/day, a high fibre diet being defined as fibre content higher than 25 g/day in
women and 38 g/day in men [13].
The influence of dietary fibre rich food on gastrointestinal functions has been increasingly
recognised [14–16]. Dietary fibre has been demonstrated to have a significant effect on fecal weight,
intestinal motility and transit time. The increase in fecal volume and weight is due to the ability
of fibre to absorb water and convey it into the bowel [17,18]. The consumption of high amounts
of fibre also leads to an increase in fecal excretion of bile acids and fats (i.e., dietary fibre induced
steatorrhea), likely related to an inhibition of pancreatic enzymes [19–22]. In vitro studies have
demonstrated that in the surface of some forms of dietary fibre, bile acids, pancreatic enzymes and
minerals can be bound [20,23–25]. Schneeman and coworkers studied the effect of purified and
unpurified fibre on enzyme activities by testing dietary fibre such as wheat bran, whole alfalfa,
rice bran, safflower flour, cellulose acetate, xylan, Solka-Floc and pectin. Chymotrypsin activity was
extensively dose-dependently reduced only by Solka-Floc purified fibre. Lipase activity, in turn, was
significantly lost with almost all of the purified and non-purified fibre tested, excluding pectin [26].
Furthermore, the addition of pectin, guar gum and wheat bran to the human duodenal juice reduces the
activity of amylase and lipase. Pectin and wheat bran also reduced the activity of trypsin, only pectin
caused a reduction in phospholipasic activity [24]. However, these studies were conducted in vitro
and how these findings can be translated to humans is currently unclear.
Fibre inhibition of pancreatic enzymes has been hypothesised to be due to compounds present
in plants, better known as “anti-nutrients” [27]. Gemede A. and Ratta N. defined anti-nutrients as
“anti-nutritional factors with negative effects or non-nutritive compounds with positive effects on
health” [28]. The negative or positive effects of these compounds depend on the specific clinical context.
Anti-nutrients can reduce blood sugar levels and insulin responses to starchy foods and/or reduce
cholesterol plasma levels and triglycerides levels, making them potentially useful as an anti-obesity
drug [29]. In turn, these anti-nutrient compounds could exacerbate malabsorption in pancreatic
insufficiency, negatively affecting the management of some pancreatic disorders. Anyhow, all studies
available on anti-nutrients are in vitro and the results must be taken with caution. The effect of
these substances should be evaluated in vivo in order to assess their effect in patients with pancreatic
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disease. Principle food sources of anti-nutrients with inhibitory effects on pancreatic enzyme activity
are reported in Table 1.
Anti-nutrients main effect is to act as pancreatic lipase inhibitors and hence to interfere with
macro- and micronutrient absorption. Different natural substances, contained in different officinal
plants and vegetables, have been screened for lipase inhibitors activity [30]. Based on their chemical
structure, these can be grouped into seven classes: saponins, polyphenols, terpenes, glycosides,
alkaloids, carotenoids and polysaccharides [31]. More specifically, the main lipase inhibitors are green
tea with epigallocatechin-3-gallate, ginseng with saponin, extracts of peanut (Arachis hypogaea),
alkaloids with caffeine, theophylline and theobromine, glycoside in Glycyrrhiza glabra, terpenes in
Salvia officinalis, procyanidin fraction of the polyphenol extract [32], as well as soybean extracts [33].
Several anti-nutrients, such as, phytic acid, lectins, tannins, saponins, act also as amylase inhibitors
and protease inhibitors [34,35].
Table 1. Main anti-nutrients acting as inhibitors of pancreatic enzymes and their food source.
Anti-Nutrients Alimentary Products
Saponins [34] soybeans
Phytate [27] grains (rice polished, wheat bran), oilseeds, legumes
Lectins [28] legumes, oilseeds (soybeans)
Trypsin inhibitors [27] soybeans, legumes (beans, peas)
Tannins [27] legumes (beans, peas), cereals (sorghum, millet)
Polyphenols [30] extracts of citrus fruits, grape seeds, tea (oolong tea), peanut shells, apples
1.2. Pathophysiology of Digestion and Absorption in Pancreatic Diseases
Temporary or long-lasting PEI is a common complication of pancreatic diseases, whose incidence
is disease-related.
Acute pancreatitis (AP) is an inflammatory condition of the pancreas that often involves
peri-pancreatic tissues and remote organ systems. The incidence of AP ranges from 5 to 30 cases
per 100,000. The severity of the disease varies widely from the most frequent mild forms to severe
disease with multi-systemic organ failure, occurring in about 10–20% of cases, that can eventually lead
to death [36–38]. A recent meta-analysis reported that PEI occurs in about 25% of patients, during
follow-up, after an AP episode. Main risk factors are an alcoholic etiology and AP severity with a
significant loss of pancreatic parenchyma [39].
Chronic pancreatitis (CP) is a fibro-inflammatory syndrome of the pancreas, characterised by
irreversible morphological changes, that typically causes abdominal pain and can eventually result
in permanent loss of the pancreatic function [40,41]. The clinical presentation of CP depends on the
disease stage: Early phases are characterised more frequently by episodes of abdominal pain, while,
as the disease progresses, signs of pancreatic exocrine and endocrine insufficiency develop [42,43].
PEI also occurs in pancreatic surgical resection, as a consequence of loss of parenchyma.
The main clinical consequence of PEI is malnutrition, consequent to maldigestion-driven
malabsorption of macro- and micronutrients, like fat-soluble vitamins, minerals and trace elements [44].
An adequate diet is a cornerstone in the management of pancreatic disease that is required to ensure
adequate nutritional intake and to limit malabsorption. For this reason, a nutritional screening becomes
crucial. According to the European Society of Clinical Nutrition and Metabolism (ESPEN), the diagnosis
of malnutrition should be based on either a low body mass index (BMI), or on the combined weight
loss associated with reduced BMI (age-specific) or a low fat-free mass index (FFMI), using sex-specific
cut-offs [45]. With the loss of pancreatic parenchyma, a status of altered blood glucose level can also
occur that is characterised by phases of hyperglycemia induced by the persistent hepatic glucose
production, but also by frequent episodes of hypoglycemia because of increased peripheral insulin
sensitivity [46,47].
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The pathogenesis of glucose homeostasis disorders in specific pancreatic disease is heterogeneous,
as the terminology used to describe it. The previous term “type 3-c diabetes”, which was used from 2002
to 2014 in the classification of diabetes by the American Diabetes Association (ADA), is now considered
old and confusing and has been replaced with the new term “diabetes of the exocrine pancreas”
(DEP) [48]. Criteria for the diagnosis of DEP, published in 2016, are as follows: 1. the presence of PEI
(confirmed by monoclonal fecal elastase-1 testing or direct function tests); 2. consistent pancreatic
abnormalities on imaging (endoscopic ultrasound, MRI, or CT scan) and; 3. absence of related
autoimmune markers of type 1 diabetes [49]. DEP is further split into two categories. ‘New onset
diabetes after pancreatitis’ (NODAP) that acknowledges the effect of acute or chronic pancreatitis on
previously normal glucose homeostasis, excluding patients with diabetes, before and up to 3 months
after hospital discharge with pancreatitis; and ‘post-pancreatitis diabetes mellitus’ (PPDM), which
describes the presence of diabetes in the setting of acute or chronic pancreatitis irrespective of the timing
of diabetes onset [48]. In literature the estimated probability to develop DEP during CP is around
30–40% [50,51]. In addition, about 40% of patients develops transient abnormal glucose metabolism
after only a single episode of AP [52,53], with increased risk of developing diabetes compared to the
general population [54].
It is important to investigate the occurrence of DEP, in order to start the correct therapy and to
avoid malnutrition and control the glycemic profile. In particular, the incretin system may play an
important role in the metabolic control of DEP, in which the regulation of the beta-cell mass and the
physiological incretin secretion are directly dependent on normal exocrine pancreatic function and fat
hydrolysis [55]. Pancreatic diseases have been associated with a functional impairment of the incretin
system [56,57]. Therefore, the mainstay of DEP is the deep interaction between exocrine and endocrine
pancreas [58].
The target of medical nutrition therapy in diabetic patients, according with the ADA, is to preserve
optimal metabolic outcome and to prevent and treat complications. People with overall diabetes
are encouraged to choose a variety of fibre-containing foods because they reduce the fasting plasma
glucose level, through their slowing effect on gastric emptying and small bowel transit. Last but
not least, fibre is able to increase insulin sensitivity. However, in DEP, a fibre-rich diet could inhibit
enzymatic activity, worsen maldigestion and consequently lead to malabsorption and incretins release.
In patients with DEP and concomitant PEI, oral pancreatic enzyme replacement therapy, necessary
for adequate fat digestion and nutrients absorption, normalises the impaired glucagon-like peptide 1
secretion, improving glucose tolerance by maintaining incretin secretion [59,60].
The objective of formulating an adequate diet for patients with pancreatic disease is precisely to
avoid unjustified food restrictions and to correct nutritional deficiencies, minimise weight loss and
prevent excessive gland stimulation to counteract the pain. Correct management of nutrition is achieved
by a suitable daily energy intake, with about 55–60% of the calories deriving from carbohydrates (in
particular complex carbohydrates and grains), 25–30% deriving from lipids and a protein intake of
about 0.8–1 g of protein for kilogram of desirable body weight [61]. While experiencing a pancreatic
disease, the nutritional recommendations are to have a personalised dietary counseling in order to
assess nutrition and clinical status including anthropometric and biochemical parameters, and finally,
to research an eventual exocrine and endocrine dysfunction affecting normal digestion and absorption
of macro- and micronutrients [62]. A personalised diet should ensure the right intake of calories and
correct nutritional deficiencies, if any, and choose tolerable food in order to reduce the worsening of
malabsorption-related abdominal symptoms and avoid the risk of insufficient food intake [63].
2. Use of Fibre in Pancreatic Diseases
As discussed previously, the effect of a high fibre diet in patients with pancreatic disease is still
debated. On the one side, studies have shown its beneficial role in AP on reducing hospital stay and
complications [64,65], on the other side, when the disease progresses and PEI occurs, fibre consumption
seems to worsen enzyme function and abdominal symptoms (i.e., diarrhea with or without steatorrhea,
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pain, bloating) [66,67]. In patients with pancreatic disorders, the correct consumption of fibre might
then require a patient-targeted prescription, that takes into account the severity of pancreatic disease,
the exocrine and the endocrine pancreatic status [62,63].
2.1. Fibre in Acute Pancreatitis
Historically, the standard therapeutic approach in the management of AP consisted of the reduction
of pancreatic exocrine secretion by “pancreatic rest” obtained via stopping oral feeding. This concept
has changed since the last decade. In the absence of ileus or vomiting, even in the acute phase,
oral feeding can be initiated early (within 24 h) as tolerated, if the pain is decreasing and inflammatory
markers are improving [36]. When patients are subjectively hungry, early refeeding with a solid,
low fat and low fibre diet may be safe, regardless of resolution of abdominal pain and normalisation of
pancreatic enzymes [68,69].
In AP, nutrition and nutritional supplements are important not only in restoring energy balance,
but also in preserving gut barrier function and providing important immunomodulatory and
antioxidant effects [70]. Intestinal barrier dysfunction is associated with translocation of bacteria,
whose inflammatory and toxic products can migrate and cause infection of the necrotic pancreas,
and in the worst scenario, can induce systemic inflammatory response syndrome (SIRS). Therefore,
conserving the integrity of the gut barrier in the small intestine is one of the main goals in early-phase
treatment of severe AP [71,72].
Prebiotics are able to regulate the homeostasis of the intestinal barrier and can be effective in the
management of patients with AP [73], even if studies that assess the effect of prebiotic in AP are scarce
and heterogeneous (Table 2). Olah and colleagues showed a beneficial effect of synbiotics on severe
AP in two randomised, double-blind clinical trials (RCT) [64,74]. In the first one, a beneficial effect on
AP-associated endotoxemia was reported in 45 patients receiving, with early enteral nutrition (EN),
either live or heat-inactivated Lactobacillus plantarum 299with oat fibre supplement. Results showed that
live probiotics were effective in reducing pancreatic sepsis and the number of surgical interventions [74].
Their next RCT study involved 62 patients who received “Synbiotic 2000”, a composition containing
four different lactobacilli preparations plus prebiotics (four bioactive fibres, inulin, beta-glucan, resistant
starch and pectin), compared to a control group, which received prebiotic alone [64]. Patients receiving
synbiotic therapy showed reduced incidence of SIRS and lower rates of organ failure, supporting the
findings that early EN with synbiotics may prevent organ dysfunctions in the late phase of severe AP.
Finally, in a randomised, double-blind study, with 30 consecutive severe AP patients, the use of EN
with only prebiotic fibre supplementation was found to shorten hospital stay, duration of nutrition
therapy and to reduce the acute phase response and overall complications, compared to standard EN
therapy [65].
Table 2. Effects of pre- and probiotic supplementation in enteral nutrition on acute pancreatitis.
Study N Patients Pre-Probiotic Group Control Group Outcomes
Olah A.
(2002) [74] 45
Live L. plantarum 299 +
oat fibre
Inactiveted L.
plantarum 299 + oat
fibre
↓ infected pancreatic necrosis (1/22
(4.5%) vs. 7/23 (30.4%) p < 0.05) and
surgical interventions (1/22 (4.5%) vs.
7/23 (30.4%) p < 0.05).
Olah A.
(2007) [64] 62
Inulin, beta-glucan,
resistant starch, pectin +
Lactobacilli
Inulin, beta-glucan,
resistant starch,
pectin
↓ incidence of SIRS and OF (8/33
(24.2%) vs. 14/29 (48.3%) p < 0.05); ↓
overall complications (9/33 (27.3%) vs.
15/29 (51.7%) p < 0.05).
Karakan T.
(2007) [65] 30 Soluble + Insoluble fibre
Standard enteral
solution
↓ hospital stay (10 ± 4 vs. 15 ± 6
p < 0.05), overall complications (7/15
(46.6%) vs. 9/15 (60%) p < 0.05).
↓: reduction; SIRS: Systemic inflammatory response syndrome; OF: Organ failure.
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However, the results of these studies concerning the efficacy of prebiotics in AP should be taken
with caution since only the study of Karakan and colleagues [65] directly demonstrated it. The other
studies showed the efficacy of synbiotics, namely a combination of prebiotic and probiotic, making it
not possible to establish the real effect of prebiotic supplementation on acute pancreatitis outcomes.
2.2. Fibre in Chronic Pancreatitis
In patients with chronic pancreatitis (CP), frequent low-volume meals and avoidance of foods
that are difficult to digest are generally recommended for the progressive appearance of pain [75].
Malabsorption of micro- and macronutrients connected to the insufficient level and/or activity of
pancreatic enzymes is the major cause of progressive nutritional and metabolic impairment in these
patients [40]. Fat restriction is no longer recommended, since studies on the fate of both endogenous
and exogenous enzymes, during small intestinal transit, show that survival of enzyme activity is
enhanced by the presence of their respective substrates [76]. This means that survival of lipase activity
during intestinal transit requires the presence of dietary triglycerides [77].
In patients with PEI, an increase of the fibre content in their diet is associated with a significant
rise in the wet fecal weight and fecal fat excretion; the excretion of fecal fat in these patients under a
high fibre diet was statistically higher than the excretion of fat in the low fibre diet [19]. The study
group was small (only 12 patients) and the amount of fibre intake (80 g/day) was far above the actual
high content fibre diet [13]. Of note is that the increase in fecal fat excretion might be due in part
to the unabsorbed lipid present in the dietary fibre or to the increased excretion of bacterial lipids.
The contribution of bacterial lipid to steatorrhea in patients with pancreatic insufficiency on a high-fibre
diet is controversial. First, the fecal flora in human subjects includes a predominant anaerobic bacterial
population that has little or no lipids in the cell wall [78–80]. Secondly, bacterial excretion in feces is not
likely to increase in response to a 1 week high fibre diet [81,82], but decreases after 3 weeks on a high
fibre diet [83]. Thus, the increase in fecal fat excretion on high fibre diet ingestion in patients with PEI is
most likely due to enhanced fat malabsorption. Indeed, it was calculated in vitro that 1.5 g% of wheat
bran, pectin, and cellulose led to maximal reduction of enzymatic activity [19]. Also, the reduction of
amylase activity by the dietary fibre may contribute towards carbohydrate maldigestion, and enhance
intestinal gas production that could contribute to abdominal pain, frequently detected in these patients.
However, it should also be mentioned that symptoms of flatulence and bloating occur even in normal
healthy western subjects when the fibre content of their diet is suddenly increased (Figure 1).
1 
 
 
Figure 1. Interaction between high content fibre diet* and pancreatic enzymes in chronic pancreatitis. *
High content fibre diet: >25 g/day in women, >38 g/day in men [12].
Furthermore, the effect of dietary fibre on pancreatic enzymes increases in an acidic environment.
This fact is particularly relevant for patients with PEI who often have, during the post-prandial
period, an acidic pH (pH < 4.0) in the upper small intestine due to impairment of bicarbonate
secretion [66,67,84].
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Besides maldigestion, patients with CP have recurrent abdominal pain that likely can be triggered
by excessive pancreatic secretion stimulation. Evidence suggests that dietary fibre can stimulate the
pancreatic gland with an undefined neurohormonal mechanism. Rats fed with a 20% wheat bran
supplemented diet for two weeks presented a significant increase in the concentration of lipase, amylase
and trypsin in pancreatic tissue [85], however, this was not observed with meals containing cellulose
and pectin [86,87]. Similar studies have not been conducted in humans.
In summary, the treatment of pancreatic exocrine deficiency begins with dietary recommendations
and pancreatic enzyme supplementation. Anyhow, the amount of fibre should be well thought out in
the prescription of a diet in patients with PEI, especially if malnutrition is concomitant. About 80% of
patients can be managed by a combination of dietary recommendations, pancreatic enzyme supplements
and analgesics, while 10–15% need oral nutritional supplements, 5% need enteral tube feeding and
around 1% require parenteral nutrition [75,88–90].
3. Conclusions
The role of fibre intake in the management of patients with pancreatic diseases is still debated
and in vivo human studies are lacking. Human studies are hindered by the lack of specific pancreatic
“disease indicators” of pancreatic exocrine function that can be helpful in clinical trials, as well as,
by the dichotomy of fibre effects between different pancreatic conditions.
In fact, data from literature shows that in acute pancreatitis, especially in early phase and in mild
disease, the use of soluble fibre can be useful to prevent local and systemic complications and to reduce
the hospital stay. However, the available studies have been mainly conducted testing the synbiotic
effect of concomitant prebiotics and probiotics supplementation. In turn, in chronic pancreatitis, the use
of fibre needs to be carefully controlled due to the reported evidence that fibre reduces the effect of
pancreatic enzymes, even if the actual recommendations of fibre use or avoidance in the nutritional
management of these patients derive almost from in vitro studies. Nevertheless, in these patients,
the use of synbiotics [91] improves absorption of micronutrients, even if it does not ameliorate the
overall nutritional status. It might be through the modulation of the dysbiosis, a condition recently
reported in patients with pancreatic disorders [92].
Translation studies and clinical trials are necessary to better define the link between pancreas
and microbiota in humans, but the new evidence of an intricate pancreas–microbiota cross talk in
healthy and pathological conditions [92] represents a good target for possible diet interventions. Since,
from the current knowledge, probiotics results are useless in acute diseases [93], possible future options
could be the use of fibre that greatly impacts microbiota. In this perspective, a topic that warrants
immediate attention is to verify the direct role of fibre effects on pancreatic exocrine secretion in vivo
in human studies. From the available in vitro data, the choice of the type of fibre to be used requires
particular attention. Pure soluble fibre extracts, deprived of anti-nutrients, could be the first choice.
In conclusion, many unanswered questions remain and there is a requirement for continued
research into many aspects of the nutritional management of pancreatic disease. At the moment,
the mainstay of the use of fibre in the management of pancreatic diseases is represented by the presence
or absence of PEI and, according to the current understanding, the use of fibre should then be patient-
and disease-targeted, considering specific case-by-case individual clinical conditions.
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